Will Novocure's market cap increase by 20% or more by the end of 2024? | Binary | | | 2 months ago | |
Sunvozertinib approval in China for EGFR Exon 20+ NSCLC by mid-2025? | Binary | | | 2 months ago | |
What will be Novocure's rank among top biotech companies by market cap by the end of 2025? | Categorical | | | 2 months ago | |
Will Optune Lua become the leading treatment for mNSCLC post-platinum chemotherapy by mid-2025? | Binary | | | 2 months ago | |
Will Optune Lua receive additional FDA approvals for other cancer indications by the end of 2025? | Binary | | | 2 months ago | |
How will Novocure's stock price change by the end of Q1 2025? | Categorical | | | 2 months ago | |
Durvalumab with chemo as standard neoadjuvant treatment for NSCLC in US by 2025? | Binary | | | 2 months ago | |
Adoption of Novocure's Optune Lua by 50% of US centers for mNSCLC by 2024? | Binary | | | 2 months ago | |
Leading treatment for mNSCLC in US by market share by end of 2025? | Categorical | | | 2 months ago | |
First region to adopt Optune Lua for mNSCLC post-US approval by end of 2025? | Categorical | | | 2 months ago | |
Leading company in NSCLC treatment innovation by end of 2025? | Categorical | | | 2 months ago | |
What percentage of mNSCLC patients will adopt Optune Lua by the end of 2025? | Categorical | | | 2 months ago | |
